-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary InterventionD Sibbing, D Aradi, D Alexopoulos et al. -
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialHahn JY, Song YB, SMART-DATE investigators et al.
-
Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II StudyMW Krucoff , P Urban, J-F Tanguay et al.
-
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS studyChen Y, Yin T, Xi S et al.
-
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial SubanalysisJurrienM Berg, A de Veer, the RE-DUAL PCI Steering Committee and Investigators et al.
-
Polymer-based or Polymer-free Stents in Patients at High Bleeding RiskS Windecker, A Latib, the ONYX ONE Investigators et al.
-
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Leonardi S, Franzone A, Piccolo R et al.
-
Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trialSong YB, Gwon HC, Hahn JY et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
